Introduction
hypertriglyceridemia, ALL
CARDIOVASCULAR DISEASE, ACUTE LYMPHOBLASTIC LEUKEMIA, DEL, SECONDARY, HYPERTRIGLYCERIDEMIA
Edited by: Jessie Zurita-Cruz, Hospital Infantil de México Federico Gómez, MexicoReviewed by: Juan Carlos Núñez-Enríquez, Instituto Mexicano del Seguro Social, Mexico; Ornella Guardamagna, University of Turin, Italy; Miguel Villasis-Keever, Mexican Social Security Institute (IMSS), MexicoThis article was submitted to Pediatric Endocrinology, a section of the journal Frontiers in EndocrinologyIncreased triglycerides (TGs) are a major risk factor for cardiovascular disease. Furthermore, hypertriglyceridemia is commonly associated with a reduction of high-density lipoprotein cholesterol (HDL-C) and an increase in atherogenic small-dense low-density lipoprotein (LDL-C) levels. Studies provide support that polyunsaturated omega-3 fatty acids (ω3-LCPUFAs) are cardioprotective and have antithrombotic and anti-inflammatory effects. The potential effects of ω3-LCPUFAs on cardiometabolic factors and anti-inflammatory actions in children with acute lymphoblastic leukemia (ALL) are limited. This is a secondary analysis of a previous clinical trial registered at clinical trials.gov (# NCT01051154) that was conducted to analyze the effect of ω3-LCPUFAs in pediatric patients with ALL who were receiving treatment.Objective: To examine the effect of supplementation with ω3-LCPUFAs on cardiometabolic factors in children with ALL undergoing treatment.